Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Observaional Multi-Center Phase IV Study to Evaluate the Efficacy and Safety of QLETLI (Adalimumab Biosimilar) in Pediatric and Juvenile Subjects With Severe Plaque Psoriasis (PISCES Trials)

NCT05803187 is registered in ClinicalTrials.gov with Bio-Thera Solutions as lead sponsor.

NCT NCT05803187
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05803187 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Observaional Multi-Center Phase IV Study to Evaluate the Efficacy and Safety of QLETLI (Adalimumab Biosimilar) in Pediatric and Juvenile Subjects With Severe Plaque Psoriasis (PISCES Trials)
Lead sponsor
Bio-Thera Solutions
Phase
Observational
Overall status
Completed
Start date
April 5, 2023
Completion date
March 30, 2025
Enrollment
80 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

plaque psoriasis